Biotech's $2 Billion Blind Date Just Ended in Tears

The architecture was ambitious. Gilead could opt into any Arcus program for $150 million to $275 million per asset. The companies would split U.S. profits 50/50 on optioned drugs, with Gilead taking exclusive rights outside the U.S. and paying Arcus royalties in the high-teens to low-20s percent range.

In 2021, Gilead exercised options on three programs for $725 million. By 2024, it invested another $320 million in equity at $21 per share to accelerate the domvanalimab program specifically.

That $320 million bet on TIGIT is looking rough right now.

The TIGIT Graveyard Is Getting Crowded

If this were just a Gilead problem, you might chalk it up to bad luck. But TIGIT inhibitors have become something of a mass grave for pharma R&D dollars.

TIGIT is a protein on immune cells that acts like a brake pedal, stopping your body from attacking tumors. The idea was simple: block the brake, let the immune system do its thing. It worked beautifully in mice. In humans? Not so much.

Roche went all-in on its TIGIT drug tiragolumab, running 12 major studies and enrolling nearly 5,000 patients. Every single pivotal trial missed its mark. The SKYSCRAPER-02 trial in small cell lung cancer failed in 2022. SKYSCRAPER-06 in non-squamous lung cancer failed in mid-2024. The flagship SKYSCRAPER-01 trial, which had shown a tantalizing early signal, ultimately failed its overall survival endpoint in late 2024. Roche eventually scrubbed tiragolumab from its pipeline entirely.

Merck fared even worse with vibostolimab. Two phase 3 trials were halted in 2024 primarily due to futility in efficacy endpoints. When your cancer drug can't outperform existing treatment, you've got a serious problem.

GSK took a $625 million write-down on related checkpoint programs. The entire field has become a cautionary tale about what happens when preclinical promise meets the messy reality of human biology.

Why the Science Keeps Failing

Scientists are starting to piece together why TIGIT drugs keep flopping, and the answer is humbling. TIGIT turns out to be more of a secondary brake than a primary one. Think of it like this: PD-1 inhibitors (drugs like Keytruda and Opdivo) are like cutting the main brake line on a car. TIGIT inhibitors are like disconnecting the parking brake. Helpful in theory, but if the car is already rolling, it doesn't add much.

The problem runs deeper than redundancy, though. Tumors are clever; when you block TIGIT, they compensate through other checkpoint pathways like Tim-3 and Lag-3. There are also no reliable biomarkers to identify which patients might actually respond, so trials enrolled broad populations and hoped for the best. Hope is not a clinical strategy.

Where Gilead Goes From Here

Gilead isn't abandoning oncology. Far from it. The company is pivoting hard toward antibody-drug conjugates (ADCs, which are basically guided missiles that deliver chemo directly to cancer cells) and CAR-T cell therapy (where a patient's own immune cells are engineered to hunt tumors).

In 2026 alone, Gilead announced a $5 billion acquisition of Tubulis for next-gen ADC technology and announced the pending acquisition of Arcellx to gain full control of anito-cel, a promising CAR-T therapy for multiple myeloma. The company expects five to seven pivotal cancer data readouts between 2025 and 2027.

As for Arcus, the company is pivoting to wholly owned programs: casdatifan (a kidney cancer drug already in phase 3) and quemliclustat (a pancreatic cancer candidate with phase 3 data expected in 2027). Gilead actually returned the rights to casdatifan after letting its option window expire, so Arcus gets to keep any upside there.

Analysts still rate Arcus a "Moderate Buy" with an average price target of $30.80, though that consensus likely reflects more hope than conviction at this point.

The Billion-Dollar Lesson

The TIGIT saga is one of the most expensive lessons in recent biotech history. Multiple companies spent billions chasing a target that worked in animal models but consistently failed in people. Roche alone burned through thousands of patients across a dozen trials before admitting defeat.

For Gilead, the silver lining is diversification. The TIGIT bet was big, but it wasn't the only bet. For Arcus, the path forward is narrower and lonelier. And for the broader industry, the message is clear: biology doesn't care how much money you throw at it.

Flagship Just Invented a New Type of Drug (No, Seriously)

Flagship Pioneering, the firm that built Moderna, just unveiled Serif Biomedicines and a brand-new drug category called Modified DNA. It promises the durability of gene therapy and the flexibility of mRNA, without rewriting your genome. The catch? It still has to prove it works in humans.